Literature DB >> 33911628

Factors Determining Treatment Response to Cryotherapy for Foot Warts.

Do-Yeop Kim1, Hyun-Sun Park1, Soyun Cho1, Hyun-Sun Yoon1.   

Abstract

Entities:  

Year:  2019        PMID: 33911628      PMCID: PMC7992748          DOI: 10.5021/ad.2019.31.4.457

Source DB:  PubMed          Journal:  Ann Dermatol        ISSN: 1013-9087            Impact factor:   1.444


× No keyword cloud information.
Dear Editor: Different clinical and biologic factors, such as disease duration, infection site, and lesion size, are associated with the treatment response to cryotherapy of cutaneous warts123. However, published data on the predictive factors of cryotherapy in the treatment of cutaneous warts showed inconsistent results34. In addition, the majority of previous studies have not controlled for confounding variables1234, or have included warts located in different anatomical sites12. Thus, we aimed to investigate the factors affecting the treatment response to cryotherapy in foot warts using multivariable analysis. We reviewed the medical records of patients having foot warts and who started cryotherapy at the SMG-SNU Boramae Medical Center from February 2016 through January 2018. All patients were followed until we confirmed that their warts completely disappeared, until they were lost to follow-up, or until February 2, 2018 (date of scheduled data extraction), whichever arrived earlier. Age, sex, disease duration, infection site (toe, sole, and periungual), number of lesions, the maximum diameter of lesions, and recurrent status (primary infection vs. re-infection) were obtained from the medical records of the initial visits. Treatment intervals, the number of cryotherapy sessions, and treatment outcomes (cleared vs. persistent) were obtained. A patient with clearance was considered a patient who no longer had visible warts and had sustained normal skin color and skin lines for at least 4 weeks after the last cryotherapy. A responder was defined as a patient having complete clearance of warts within after 6 cryotherapy sessions5. The study protocol was approved by the Institutional Review Board of the SMG-SNU Boramae Medical Center (approval number: 30-2017-30) and the requirement for informed consent was waived. The liquid nitrogen was delivered by cryo-spray until a halo of frozen tissue appeared around the wart, and this was maintained for 10 seconds. Warts were treated with a triple freeze-thaw cycle, with complete thawing of the frozen tissue between the cycles. Before cryotherapy, warts were pared to remove the hyperkeratotic skin without bleeding. Logistic regression analyses were used to evaluate associations between predictive factors and treatment response. Predictive factors showing univariable associations with treatment response (p<0.20) were included in a multivariable logistic regression model. A total of 89 patients were identified who received cryotherapy for foot warts (Table 1). At the time of database extraction, patients had been followed for a median of 109 days (range, 10~630 days). A total of 47 patients (52.8%) achieved complete clearance within 6 cryotherapy sessions (responders). As shown in Table 2, the univariable logistic regression analysis revealed that male sex, longer disease duration, higher lesion number, larger size (≥1 cm), and longer treatment intervals (>3 weeks) were associated with lower treatment response (Table 2). The mean treatment intervals were 16.4 days in a shorter interval group (mean treatment interval ≤3 weeks) and 33.0 days in the longer interval group (mean treatment interval >3 weeks). There were no significant differences in treatment response according to age, infection site, and recurrent status.
Table 1

Demographic and clinical characteristics of patients

VariableAll patients (n=89)
Age (yr)12.0 (9.0~24.0)
Sex
 Male62 (69.7)
 Female27 (30.3)
Duration (mo)6.5 (2.0~21.0)
Infection site
 Toe*34 (38.2)
 Sole50 (56.2)
 Periungual5 (5.6)
Lesion number2.0 (1.0~3.0)
Lesion size
 <1 cm63 (70.8)
 ≥1 cm26 (29.2)
Recurrent status
 Primary infection64 (71.9)
 Re-infection25 (28.1)
N of treatment4.0 (2.0~9.0)
Treatment intervals
 ≤3 weeks49 (55.1)
 >3 weeks40 (44.9)

Values are presented as median (interquartile range) or number (%). *Whole part of toes including web spaces, except perionychium. †Wart involving the perionychium.

Table 2

Univariable and multivariable analysis of treatment response to cryotherapy in foot warts (n=89)

VariableUnivariable analysisMultivariable analysis
Response (n=47)*Non-response (n=42)OR (95% CI)p-valueOR (95% CI)p-value
Age (yr)11.0 (8.5~24.0)16.5 (10.0~24.0)0.962 (0.917~1.008)0.1071.018 (0.953~1.089)0.592
Sex
 Female19 (40.4)8 (19.0)ReferenceReference
 Male28 (59.6)34 (81.0)0.347 (0.132~0.911)0.0320.494 (0.137~1.779)0.281
Duration (mo)5.0 (1.0~8.5)12.0 (6.0~24.0)0.963 (0.935~0.992)0.0130.980 (0.946~1.016)0.271
Infection site
 Toe22 (46.8)12 (28.6)ReferenceReference
 Sole23 (48.9)27 (64.3)0.465 (0.190~1.139)0.0940.530 (0.155~1.811)0.311
 Periungual2 (4.3)3 (7.1)0.364 (0.053~2.487)0.3020.308 (0.027~3.556)0.345
Lesion number1.0 (1.0~2.0)3.0 (2.0~6.0)0.561 (0.400~0.788)0.0010.631 (0.451~0.883)0.007
Lesion size
 <1 cm41 (87.2)22 (52.4)ReferenceReference
 ≥1 cm6 (12.8)20 (47.6)0.161 (0.056~0.460)0.0010.570 (0.132~2.462)0.452
Recurrent status
 Primary infection33 (70.2)31 (73.8)Reference-
 Re-infection14 (29.8)11 (26.2)1.196 (0.472~3.029)0.706-
Treatment intervals
 ≤3 weeks35 (74.5)14 (33.3)ReferenceReference
 >3 weeks12 (25.5)28 (66.7)0.171 (0.069~0.429)<0.0010.161 (0.050~0.517)0.002

Values are presented as median (interquartile range), OR (95% CI), or number (%). OR: odds ratio, CI: confidence interval. *Treatment response was defined as complete clearance of warts within 6 sessions. †Whole part of toes including web spaces, except perionychium. ‡Wart involving the perionychium.

In the multivariable logistic regression analysis, two variables (lesion number, and treatment intervals) remained significantly associated with treatment response (Table 2). A higher number of lesions was significantly associated with lower treatment response (odds ratio [OR] per one lesion-increase, 0.631; 95% confidence interval [CI], 0.451~0.883; p=0.007). Additionally, the longer interval group showed lower treatment response compared with the shorter interval group (OR, 0.161; 95% CI, 0.050~0.517; p=0.002) (Table 2). However, age, sex, disease duration, infection site, and lesion size were no longer significantly associated with lower treatment response after adjusting for covariates. We found that longer treatment intervals led to a poor clinical outcome. The associations between treatment intervals and clearance after cryotherapy remain unclear, with conflicting results from previous studies46. However, previous studies included both hand and foot warts and did not compare >3 week and ≤3 week intervals. Furthermore, the retrospective analysis did not use multivariable analyses to adjust for covariates4. We found that several variables were not significantly associated with the treatment response in the multivariable analysis despite significant associations in univariable analyses. In this study, higher number of warts was associated with a lower clearance rate. Human papillomavirus infections are normally controlled by an intact cell-mediated and humoral immune system7. Therefore, patients with cell-mediated immunodeficiency are at increased risk of developing extensive, persistent, and recurrent warts8. Similarly, a higher number of warts might indicate lower immunity against warts. We found that sex, disease duration, and lesion size were not associated with treatment response to cryotherapy. These findings are contrary to those of previous studies23. Ahmed et al.2 found that warts that had been present for 6 months or less had a greater chance of clearing (84%) within 3 months than warts that had been present for more than 6 months (39%). Berth-Jones and Hutchinson3 also reported that the disease duration and lesion size were significant predictors of response. This discrepancy could be partly explained by differences in the statistical methods used as previous studies did not adjust for confounding factors. We found disease duration and lesion size were associated with treatment response using univariable analyses, whereas these associations were no longer significant after adjusting for covariates. Our study had several limitations. Similar to other retrospective chart review studies, there is a possibility that unmeasured confounding factors were present in our series. However, there were no missing data on independent variables in this study because we had started to document all the above-mentioned variables of patients with cutaneous warts at the initial visit as of February 2016, and we adjusted for covariates in our analysis contrary to previous studies123910. In addition, we only included patients with foot warts in our cohort; therefore, our results may not be generalizable to all cutaneous warts. Despite these limitations, our results suggested an effective treatment strategy for cryotherapy of foot warts. Clinicians could consider aggressive cryotherapy from the beginning of the treatment of foot warts if a patient has many lesions. In addition, if the treatment response to cryotherapy is unsatisfactory, clinicians could consider reducing the treatment interval to improve the treatment response.
  9 in total

1.  Liquid nitrogen cryotherapy of common warts: cryo-spray vs. cotton wool bud.

Authors:  I Ahmed; S Agarwal; A Ilchyshyn; S Charles-Holmes; J Berth-Jones
Journal:  Br J Dermatol       Date:  2001-05       Impact factor: 9.302

2.  Modern treatment of warts: cure rates at 3 and 6 months.

Authors:  J Berth-Jones; P E Hutchinson
Journal:  Br J Dermatol       Date:  1992-09       Impact factor: 9.302

Review 3.  Generalized verrucosis: a review of the associated diseases, evaluation, and treatments.

Authors:  Jennifer C Sri; Meghan I Dubina; Grace F Kao; Peter L Rady; Stephen K Tyring; Anthony A Gaspari
Journal:  J Am Acad Dermatol       Date:  2011-05-14       Impact factor: 11.527

4.  A Two-week Interval Is Better Than a Three-week Interval for Reducing the Recurrence Rate of Hand-foot Viral Warts after Cryotherapy: A Retrospective Review of 560 Hand-foot Viral Warts Patients.

Authors:  Sung Hwan Youn; In Ho Kwon; Eun Joo Park; Kwang Ho Kim; Kwang Joong Kim
Journal:  Ann Dermatol       Date:  2011-02-28       Impact factor: 1.444

5.  British Association of Dermatologists' guidelines for the management of cutaneous warts 2014.

Authors:  J C Sterling; S Gibbs; S S Haque Hussain; M F Mohd Mustapa; S E Handfield-Jones
Journal:  Br J Dermatol       Date:  2014-10-01       Impact factor: 9.302

6.  Cryotherapy of common viral warts at intervals of 1, 2 and 3 weeks.

Authors:  J F Bourke; J Berth-Jones; P E Hutchinson
Journal:  Br J Dermatol       Date:  1995-03       Impact factor: 9.302

7.  Cryotherapy with liquid nitrogen versus topical salicylic acid application for cutaneous warts in primary care: randomized controlled trial.

Authors:  Sjoerd C Bruggink; Jacobijn Gussekloo; Marjolein Y Berger; Krista Zaaijer; Willem J J Assendelft; Margot W M de Waal; Jan Nico Bouwes Bavinck; Bart W Koes; Just A H Eekhof
Journal:  CMAJ       Date:  2010-09-13       Impact factor: 8.262

8.  Cryotherapy versus salicylic acid for the treatment of plantar warts (verrucae): a randomised controlled trial.

Authors:  Sarah Cockayne; Catherine Hewitt; Kate Hicks; Shalmini Jayakody; Arthur Ricky Kang'ombe; Eugena Stamuli; Gwen Turner; Kim Thomas; Mike Curran; Gary Denby; Farina Hashmi; Caroline McIntosh; Nichola McLarnon; David Torgerson; Ian Watt
Journal:  BMJ       Date:  2011-06-07

9.  Humoral and cell-mediated immunity to human papillomavirus type 1 (HPV-1) in human warts.

Authors:  J L Kienzler; M T Lemoine; G Orth; N Jibard; D Blanc; R Laurent; P Agache
Journal:  Br J Dermatol       Date:  1983-06       Impact factor: 9.302

  9 in total
  1 in total

1.  Good Clinical Responders to Topical Timolol in Patients with Infantile Hemangiomas: A 7-Year Retrospective Study of 328 Korean Patients.

Authors:  Da-Ae Yu; Se Hee Min; Jaeryong Song; Jong Seo Park; Hanjae Lee; Jungyoon Ohn; Kyu Han Kim
Journal:  Ann Dermatol       Date:  2022-10       Impact factor: 0.722

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.